Process optimization, characterization and evaluation in vivo of oxymatrine-phospholipid complex

International Journal of Pharmaceutics

Volumn 387, Issue 1-2, 2010, Pages 139-146

  Yue, Peng Fei ^a,b   Yuan, Hai Long ^c   Li, Xian Yi ^c   Yang, Ming ^a   Zhu, Wei Feng ^a  

^a JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c BEIJING 302 HOSPITAL   (China)

Author keywords

Optimization; Oxymatrine; Pharmacokinetics; Phospholipid complex; Physicochemical properties

Indexed keywords

OXYMATRINE; PHOSPHOLIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CAPILLARY ELECTROPHORESIS; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DETERMINATION; DRUG FORMULATION; DRUG MIXTURE; DRUG PENETRATION; DRUG SOLUBILITY; EXPERIMENTAL RAT; IN VIVO STUDY; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; TEMPERATURE SENSITIVITY; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ALKALOIDS; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HEPATOCYTES; LINEAR MODELS; MALE; PERMEABILITY; PHOSPHOLIPIDS; QUINOLIZINES; RATS; SOLUBILITY; TIME FACTORS; X-RAY DIFFRACTION;

EID: 77649188639     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.12.008     Document Type: Article

References (21)

1. Chen Y., Li J., Zeng M., Lu L., Qu D., Mao Y., Fan Z., Hua J. The inhibitory effect of oxymatrine on hepatitis C virus in vitro. Zhonghua Ganzangbing Zazhi 2001, 9(Suppl.):12-14.
2. Chen X.S., Wang G.J., Cai X., Yu H.Y., Hu Y.P. Inhibition of hepatitis B virus by oxymatrine in vivo. World J. Gastroenterol. 2001, 7:49-52.
3. Chen Y.X., Mao B.Y., Jiang J.H. Relationship between serum load of HBV-DNA and therapeutic effect of oxymatrine in patients with chronic hepatitis B. Zhongguo Zhongxiyi Jiehe Zazhi 2002, 22:335-336.
4. Dévay A., Mayer K., Pál S., Antal I. Investigation on drug dissolution and particle characteristics of pellets related to manufacturing process variables of high-shear granulation. J. Biochem. Biophys. Methods 2000, 69:197-205.
5. Dong Y., Xi H., Yu Y., Wang Q., Jiang K., Li L. Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of oxymatrine. J. Gastroenterol. Hepatol. 2002, 17:1299-1306.
6. Fariss M.W., Brown M.K., Schmitz J.A., Reed D.J. Mechanisms of chemical-induced toxicity. I. Use of a rapid centrifugation technique for the separation of viable and nonviable hepatocytes. Toxicol. Appl. Pharmacol. 1985, 79:283-295.
7. Fariss M.W., Merson M.H., O'Hara T.M. Alpha-tocopheryl succinate protects hepatocytes from chemical-induced toxicity under physiological calcium conditions. Toxicol. Lett. 1989, 47:61-75.
8. Krogars K., Heinamaki J., Vesalahti J., Marvola M., Antikainen O., Yliruusi J. Extusion-spheronization of pH-sensitive polymeric matrix pellets for possible drug delivery. Int. J. Pharm. 2000, 199:187-194.
9. Lai J.P., He X.W., Jiang Y., Chen F. Preparative separation and determination of matrine from the Chinese medicinal plant Sophora flavescens Ait by molecularly imprinted solid-phase extraction. Anal. Bioanal. Chem. 2003, 375:264-269.
10. Lasonder E., Weringa W.D. An NMR and DSC study of the interaction of phospholipids vesicles with some anti-inflammatory agents. J. Colloid Interface Sci. 1990, 139:469-478.
11. Li J., Li C., Zeng M. Preliminary study on therapeutic effect of oxymatrine in treating patients with chronic hepatitis C. Zhongguo Zhongxiyi Jiehe Zazhi 1998, 18:227-229.
12. Li Y., Pan W.S., Chen S.L., Yang D.J., et al. Studies on Preparation of Puerarin Phytosomes and their Solid Dispersion. Chinese Pharm. J. 2006, 41:1162-1167.
13. Liu J., Manheimer E., Tsutani K., Gluud C. Medicinal herbs for hepatitis C virus infection: a cochrane hepatobiliary systematic review of randomized trials. Am. J. Gastroenterol. 2003, 98:538-544.
14. Luo M., He P., Wu M. Determination of matrine and oxymatrine by HPCE. J. Chin. Tradit. Herbal Drugs 1999, 30(4):261-263.
15. Menggendalai, Wang Y., Jia F.-Q. Reversed phase ion-pair HPLC determination of oxymatrine and matrine in human plasma. Chin. J Pharm. Anal. 2003, 23(6):440.
16. Venema F.R., Weringa W.D. The interactions of phospholipid vesicles with some anti-inflammatory agents. J. Colloid Interface Sci. 1988, 125:484-500.
17. Wang S.J., Wang G.J., Li X.T., Mang R.L., et al. Pharmacokinetics of oxymatrine and its metabolite in beagle dogs by LC-MS. Chin. J. Chinese Mat. Med. 2005, 30(2):133-136.
18. Wang B.E. Treatment of chronic liver diseases with traditional Chinese medicine. J. Gastroenterol. Hepatol. 2000, 15(Suppl.):67-70.
19. Xiang X., Wang G., Cai X., Li Y. Effect of oxymatrine on murine fulminant hepatitis and hepatocyte apoptosis. Chin. Med. J. 2002, 115:593-596.
20. Yang W., Zeng M., Fan Z., Mao Y., Song Y., Jia Y., Lu L., Chen C.W., Peng Y.S., Zhu H.Y. Prophylactic and therapeutic effect of oxymatrine on d-galactosamine-induced rat liver fibrosis. Zhonghua Ganzangbing Zazhi 2002, 10:193-196.
21. Yu Y.Y., Wang Q.H., Zhu L.M., Zhang Q.B., Xu D.Z., Guo Y.B., Wang C.Q., Guo S.H., Zhou X.Q., Zhang L.X. A clinical research on oxymatrine for the treatment of chronic hepatitis B. Zhonghua Ganzangbing Zazhi 2002, 10:280-281.